title: Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
authors.affiliation: Division of Cardiology, University of Colorado Health Sciences Center, 4200 E Ninth Ave, B-130, Denver, CO 80262, USA. joann.lindenfeld@UCHSC.edu
authors.forename: JoAnn
authors.initials: J
authors.lastname: Lindenfeld
authors.forename: Geraldine G
authors.initials: GG
authors.lastname: Miller
authors.forename: Simon F
authors.initials: SF
authors.lastname: Shakar
authors.forename: Ronald
authors.initials: R
authors.lastname: Zolty
authors.forename: Brian D
authors.initials: BD
authors.lastname: Lowes
authors.forename: Eugene E
authors.initials: EE
authors.lastname: Wolfel
authors.forename: Luisa
authors.initials: L
authors.lastname: Mestroni
authors.forename: Robert L
authors.initials: RL
authors.lastname: Page
authors.forename: Jon
authors.initials: J
authors.lastname: Kobashigawa
mesh_terms: D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000963:Antimetabolites / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000068338:Everolimus; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control*; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016027:Heart Transplantation / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011494:Protein Kinases / Q000187:drug effects; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000009:adverse effects* / Q000276:immunology
chemical_list: D000305:Adrenal Cortex Hormones; D000963:Antimetabolites; D065095:Calcineurin Inhibitors; D006131:Growth Inhibitors; D007166:Immunosuppressive Agents; D047428:Protein Kinase Inhibitors; D016572:Cyclosporine; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D009173:Mycophenolic Acid; D001379:Azathioprine; D020123:Sirolimus; D016559:Tacrolimus